FindTrial
Sign In

Granulocyte Colony-Stimulating Factor(G-CSF)

DRUG6 trials

Sponsors

Nanfang Hospital, Southern Medical University, Nanjing University, Ruijin Hospital

Conditions

Acute Myeloid Leukemia (AML)Allogeneic Hematopoietic Stem Cell TransplantationConditioningFemale InfertilityMyelodysplastic SyndromeMyelodysplastic Syndromes (MDS)Secondary Acute Myeloid Leukemia Evolving From MDSThin Endometrium

Phase 2

G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
CompletedNCT02744742
Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome
Start: 2016-04-18End: 2021-09-30Updated: 2022-02-14
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
NCT04713956
Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome
Start: 2021-01-15End: 2024-07-31Target: 242Updated: 2021-01-19
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for Secondary Acute Myeloid Leukemia Undergoing Allo-HSCT
NCT05449899
Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Secondary Acute Myeloid Leukemia Evolving From MDS
Start: 2022-07-31End: 2024-12-31Target: 232Updated: 2022-07-08
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for High-risk MDS Undergoing Allo-HSCT
NCT05453552
Nanfang Hospital, Southern Medical UniversityAllogeneic Hematopoietic Stem Cell Transplantation, Conditioning, Myelodysplastic Syndrome
Start: 2022-07-01End: 2024-12-31Target: 242Updated: 2023-03-21

Phase 3

Intrauterine G-CSF Infusion for Thin Endometrium
Not yet recruitingNCT07692672
Nanjing UniversityFemale Infertility, Thin Endometrium
Start: 2026-10-01End: 2029-08-01Target: 620Updated: 2026-07-09
Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML
Not yet recruitingNCT07735117
Ruijin HospitalAcute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Start: 2026-07-30End: 2029-07-31Target: 168Updated: 2026-07-29

Related Papers

The effect of granulocyte-colony stimulating factor, decitabine, and busulfan-cyclophosphamide versus busulfan-cyclophosphamide conditioning on relapse in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia evolving from myelodysplastic syndrome undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised, phase 3 trial.
2023-01-2319 citations
Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
Blood2022-11-15